Viewing Study NCT05668767

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:53 AM
Ignite Modification Date: 2026-06-17 @ 5:07 AM
Study NCT ID: NCT05668767
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-12-30
First Post: 2022-12-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Sponsor: Beijing Chest Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Extensive-stage Small-cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SCLC View